definiens: ( as such term is defined in Section 3.9.4(c))correspondence between MERCK and such Regulatory Authorities relating to such Regulatory Filings, Drug ApprovalApplications and Regulatory Approvals ; ( v ) unless expressly prohibited by any Regulatory Authority, transfer sponsorship andcontrol to [COMPANY] of all Clinical Trials of Products being conducted for the Transferred Indication as of the effective date oftermination and continue to conduct such trials after the effective date of termination to enable such transfer to be completedwithout interruption of any such trial, for a reasonable period, but in no event longer than three ( 3 ) months, with the cost of suchclinical trials after the effective date of termination being at [COMPANY] ’s expense ; ( vi ) cooperate with [COMPANY], cause its Affiliates tocooperate with [COMPANY] and use Commercially Reasonable Efforts to require any Third Party with which MERCK has anagreement with respect to the conduct of Clinical Trials for Products for the Transferred Indication or the Manufacture ofProducts ( including, without limitation, agreements with contract manufacturing organizations, contract research organizations, clinical sites and investigators ), to cooperate with [COMPANY] in order to accomplish the obtaining by [COMPANY] of similar rights forthe Transferred Indication as held by MERCK under its agreements with such Third Parties ; and ( vii ) provide [COMPANY] with copiesof all reports and data generated or obtained by MERCK or its Affiliates pursuant to this Agreement that relate to the TransferredIndication that have not previously been provided to [COMPANY]